Oral drugs commonly used in ovarian cancer targeted therapy include PARP inhibitors and anti-angiogenic drugs, mainly including the following three kinds: 1. PARP inhibitors: mainly including olaparib, niraparib and lucaparib, currently domestic fluzoparib has been marketed, and three kinds of drugs are available in China: niraparib, olaparib and fluzoparib, and lucaparib has been marketed in the United States, but not yet in China. For patients with genetic mutations or patients with homologous recombination defects, after maintenance treatment with PARP inhibitors, patients’ five-year survival rate can be greatly extended, and disease-free survival time and quality of life can be greatly improved. Therefore, when ovarian cancer patients undergo primary surgery, genetic testing is generally advocated to initially determine whether PARP inhibitors can be used for treatment; 2.Anti-angiogenic drugs: commonly used include bevacizumab, and small molecule anti-angiogenic drugs such as tyrosine kinase inhibitors, there are also more domestic drugs, mainly bevacizumab, which can be taken orally with Anrotinib, Apatinib, etc., but there are related side effects. Immunotherapeutic drugs: Because most clinical trials in ovarian cancer end in failure, they are less used.